Trials / Completed
CompletedNCT01865747
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 658 (actual)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabozantinib tablets | |
| DRUG | Everolimus (Afinitor) tablets |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2015-05-22
- Completion
- 2021-01-15
- First posted
- 2013-05-31
- Last updated
- 2021-04-27
- Results posted
- 2017-07-18
Locations
205 sites across 26 countries: United States, Argentina, Australia, Austria, Belgium, Canada, Chile, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Netherlands, Poland, Portugal, Russia, Slovakia, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT01865747. Inclusion in this directory is not an endorsement.